Aurinia Pharmaceuticals Company Profile (NASDAQ:AUPH)

Analyst Ratings

Consensus Ratings for Aurinia Pharmaceuticals (NASDAQ:AUPH) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $8.25 (142.59% upside)

Analysts' Ratings History for Aurinia Pharmaceuticals (NASDAQ:AUPH)
Show:
DateFirmActionRatingPrice TargetActions
7/6/2016Leerink SwannReiterated RatingOutperform$7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/30/2016HC WainwrightInitiated CoverageBuy$7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/9/2016FBR & CoReiterated RatingBuy$9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/8/2015MLV & Co.Initiated CoverageBuy$9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Aurinia Pharmaceuticals (NASDAQ:AUPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
3/31/2015($0.11)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2014Q3 14($0.08)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aurinia Pharmaceuticals (NASDAQ:AUPH)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.14)($0.14)($0.14)
Q2 20161($0.15)($0.15)($0.15)
Q3 20161($0.15)($0.15)($0.15)
Q4 20161($0.12)($0.12)($0.12)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Aurinia Pharmaceuticals (NASDAQ:AUPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Aurinia Pharmaceuticals (NASDAQ:AUPH)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Aurinia Pharmaceuticals (NASDAQ:AUPH)
DateHeadline
07/28/16 06:56 PMAurinia Pharmaceuticals to Host Lupus Nephritis Expert Breakfast and Webcast on August 4th in New York - [Business Wire] - Aurinia Pharmaceuticals Inc. today announced it will host a Lupus Nephritis expert breakfast on Thursday, August 4th from 8:00am to 9:30am EDT in New York.
07/11/16 09:50 AMAurinia Announces Appointment of Head of Communications & Advocacy - [Business Wire] - Aurinia Pharmaceuticals Inc. , a clinical stage pharmaceutical company focused on the global nephrology market, today announced that it has appointed Celia Economides to the newly created position of Associate Vice President, Corporate Communications & Patient Advocacy.
07/05/16 07:26 AMAurinia Pharmaceuticals: Looking Even Better
07/01/16 10:42 AMAurinia Pharmaceuticals Inc (NASDAQ:AUPH) stock price target bumped up to $7 as covered today by H.C. Wainwright
06/30/16 06:16 AMCoverage initiated on Aurinia Pharma by H.C. Wainwright -
06/29/16 10:52 AMAurinia Pharmaceuticals : Announces 24 Week Remission Rates from the First Seven Patients in its Open Label AURION Study in Lupus Nephritis (LN)
06/28/16 05:45 PMAurinia Announces 24 Week Remission Rates from the First Seven Patients in its Open Label AURION Study in Lupus Nephritis (LN) - [Business Wire] - Aurinia Pharmaceuticals Inc. announced today that it has completed an analysis of the first 7 patients to complete 24 weeks in its open-label AURION study.
06/23/16 04:09 PMAurinia Pharmaceuticals Inc. (AUPH) Down on Private Placement
06/22/16 04:15 PMAurinia Announces Closing of US$7 Million Private Placement - [Business Wire] - Aurinia Pharmaceuticals Inc. has completed its previously announced private placement of 3,000,000 units of the Company at US$2.36 per unit for total gross proceeds of US$7,080,000 .
06/16/16 07:03 AMMost Active Stocks on Retreat – AUPH, NVLS, GBT, BOBE, CRAY, SALT
06/15/16 02:44 PMMid-Day Market Update: Patriot National Climbs Following Offer from Ebix; Carbylan Therapeutics Shares Tumble
06/15/16 02:44 PMMid-Morning Market Update: Markets Open Higher; Aegerion Pharmaceuticals And QLT Agree To Merge
06/15/16 02:44 PMAurinia Pharmaceuticals raises US$7mln for lupus drug development
06/09/16 06:29 PMAurinia Announces Results of Annual General Meeting - [Business Wire] - Aurinia Pharmaceuticals Inc. is pleased to announce that the six incumbent directors of the Company were re-elected at the Company’s annual general meeting held on June 8, 2016 .
06/01/16 11:27 AMAurinia Pharmaceuticals, Inc. :AUPH-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 -
02/11/16 12:47 PMAurinia to Host Conference Call & Webcast to Review Results from the AURION Study - [Business Wire] - Aurinia Pharmaceuticals Inc. will host a conference call and live webcast to discuss detailed results from its open label, single arm exploratory AURION study on Tuesday, February 16 at 4:30pm Eastern Standard Time.
02/08/16 02:02 PMAurinia Pharmaceuticals Inc (AUPH) Shares Jump 19.5% on Positive Phase 2 Results for Voclosporin - Independent Reporter - Aurinia Pharmaceuticals Inc (AUPH) Shares Jump 19.5% on Positive Phase 2 Results for VoclosporinIndependent ReporterShares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) are up big today after it was announced that the company achieved positive results in their AURION study, which examined a Lupus Nephritis treatment. Seven out of seven patients who received a ...Prelim. AURION Phase 2 Results Show Aurinia Pharma's (AUPH) Voclosporin is Viable in LN - FBRStreetInsider.comAurinia Pharmaceuticals Shares Rise 25% Pre-Bell on Preliminary Topline Data From Lupus Nephritis Study (NASDAQ ...WallStreet.orgAurinia Announces Preliminary Topline Data From its Open Label Aurion Study in Lupus NephritisYahoo Finance UKSeeking Alphaall 9 news articles »
02/08/16 02:02 PMAurinia Pharmaceuticals (AUPH) Issues Positive Update on AURION Study in Lupus Nephritis - Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH) announced that it has completed a preliminary analysis of its AURION (Aurinia early Urinary protein Reduction Predicts Response) study. In the first seven patients that have reached at least eight weeks of ...
02/08/16 07:30 AMAurinia Announces Preliminary Topline Data From its Open Label Aurion Study in Lupus Nephritis - [Business Wire] - Aurinia Pharmaceuticals Inc. announced today that it has completed a preliminary analysis of its AURION study.
02/07/16 01:05 PMAurinia Pharmaceuticals Ord (NASDAQ:AUPH) Short Interest Increased By 8.14% - fdanewsalert.com - Aurinia Pharmaceuticals Ord (NASDAQ:AUPH) Short Interest Increased By 8.14%fdanewsalert.comThe stock of Aurinia Pharmaceuticals Ord (NASDAQ:AUPH) registered an increase of 8.14% in short interest. AUPH's total short interest was 71,700 shares in February as published by FINRA. Its up 8.14% from 66,300 shares, reported previously. With 37,400 ...
02/04/16 03:30 PMAurinia Pharmaceuticals to Attend Two Upcoming Investor Conferences - [Business Wire] - Aurinia Pharmaceuticals Inc., today announced that its Chief Operating Officer Michael R. Martin will attend two upcoming investor conferences. A general corporate overview will be provided in presentation format during the Source Capital 2016 Disruptive Growth & Healthcare Conference on February 10th, 2016, while a fireside chat & discussion will occur at the 5th Annual Leerink Global Healthcare Conference ...
02/02/16 03:43 PMAurinia Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference - [Business Wire] - Aurinia Pharmaceuticals Inc., today announced that its Chief Operating Officer, Michael R. Martin will present a corporate overview of the company at the 18th annual BIO CEO & Investor Conference, taking place February 8 & 9, 2016 in New York at the Waldorf Astoria Hotel.
02/02/16 01:11 PMSentiment And Earnings Update For Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) - Investor Newswire - Sentiment And Earnings Update For Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)Investor NewswireZacks Research, combined analysts opinion on Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) and gave an average broker rating of 1. The research firm rating mechanism takes into account the research firms' forecasts on a one to five scale. As per the ...and more »
01/29/16 05:53 PMAurinia Pharmaceuticals to Present at the Canaccord Genuity Rare Disease and Bio-Pharma One on One Day - [Business Wire] - Aurinia Pharmaceuticals Inc., today announced that its President and CEO Stephen Zaruby will attend and discuss the corporate overview of the company at the Canaccord Genuity Rare Disease and Bio-Pharma One on One Day, taking place February 2nd, 2016 in New York at the Omni Berkshire Place Hotel.
01/21/16 12:06 PMAnalysts Issue Earnings Forecast For Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) - Investor Newswire - Analysts Issue Earnings Forecast For Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)Investor NewswireAccording to analysts surveyed by Zacks Research, Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is expected to post earnings of $-0.16 per share for its most recent quarter. The company is set to release its earnings around 2016-04-04. Since the same set ...and more »
01/19/16 04:20 PM5:20 pm Aurinia Pharma completes patient enrollment in its phase 2B AURA-LV study in Lupus Nephritis -
01/19/16 04:17 PMAurinia Announces Completion of Patient Enrollment in Its Phase 2B AURA-LV Study in Lupus Nephritis - [Business Wire] - Aurinia Pharmaceuticals Inc. announced today that it has fully enrolled the AURA study at 265 patients .
12/18/15 08:48 AMAurinia Pharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers -
12/15/15 07:25 AMDermira (DERM) Looks Good: Stock Adds 5.9% in Session -
12/08/15 12:11 PMAURINIA PHARMACEUTICALS INC. Financials -
11/24/15 07:35 AMIgnyta (RXDX) Looks Good: Stock Jumps 7.1% in Session -
11/24/15 07:30 AMAurinia Pharmaceuticals Announces Outcome from Data and Safety Monitoring Board for Its Phase 2b Study in Lupus Nephritis – Study to Continue as Planned - [Business Wire] - Aurinia Pharmaceuticals Inc. has announced today that the independent Data and Safety Monitoring Board for the Company's Phase 2b lupus nephritis study, known as AURA-LV, has completed its third pre-planned safety review of patients enrolled in the study and recommended continuation of the trial without any modifications.
11/13/15 03:32 PMAurinia reports 3Q loss -
11/13/15 03:15 PMAurinia Reports Third Quarter 2015 Financial Results - [Business Wire] - Aurinia Pharmaceuticals Inc. has released its financial results for the third quarter ended September 30, 2015. Amounts, unless specified otherwise, are expressed in U.S.

Social

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals logoAurinia Pharmaceuticals Inc. (Aurinia) is a Canada-based is a clinical stage pharmaceutical company. The Company is focused on the development of its therapeutic immunomodulating drug candidate, voclosporin, which is a calcineurin inhibitor (CNI). Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. Voclosporin is used as a treatment for lupus nephritis (LN). LN is an inflammation of the kidney that if untreated or inadequately treated can lead to end-stage renal disease, the requirement for life-long dialysis, or death. The Company had completed two Phase III studies of voclosporin in patients with moderate to severe psoriasis. The Company had completed a Phase IIb clinical trial of voclosporin in de novo renal transplant recipients. The Company's wholly owned subsidiaries include Aurinia Pharmaceuticals, Inc. and Aurinia Pharma Limited.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AUPH
  • CUSIP:
Key Metrics:
  • Previous Close: $3.40
  • 50 Day Moving Average: $2.8828
  • 200 Day Moving Average: $2.6459
  • P/E Ratio: N/A
  • P/E Growth: 0.0000
  • Market Cap: $109.80M
  • Beta: 2.93
  • Current Year EPS Consensus Estimate: $-0.5400 EPS
  • Next Year EPS Consensus Estimate: $-0.6200 EPS
Additional Links:
Aurinia Pharmaceuticals (NASDAQ:AUPH) Chart for Saturday, July, 30, 2016